DEFINITION & MICROBIOLOGY
- Classification: Gram-negative, microaerophilic spiral bacterium (S-shaped rod).
- Localization: Exclusively colonizes human stomach; localizes deep within the mucosal layer.
- Enzymatic Profile: Produces abundant urease, catalase, and oxidase.
- Morbidity: Classified as a Group I carcinogen; causes chronic active gastritis, peptic ulcer disease (PUD), gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma.
VIRULENCE FACTORS & PATHOPHYSIOLOGY
| Factor | Mechanism of Action |
|---|---|
| Urease Enzyme | Converts gastric urea to ammonia; neutralizes highly acidic local environment (pH 2.0) to neutral pH (5.5-7.5), creating a survival microenvironment. |
| Flagella & Chemotaxis | Provide corkscrew motility; allow migration through the mucus layer toward the gastric epithelium guided by pH gradients. |
| Adhesins (BabA, SabA) | Bind to Lewis b ABO blood group antigens and sialic acid on host gastric epithelium; mediate initial attachment and colonization. |
| CagA (Cytotoxin-associated gene A) | Oncoprotein injected via Type IV Secretion System (T4SS); alters host cell cytoskeleton; induces massive IL-8 production; strongly associated with acute gastritis and PUD risk. |
| VacA (Vacuolating Cytotoxin) | Embeds into host cell membranes; disrupts epithelial barrier function; induces massive intracellular vacuoles leading to cell collapse and death. |
ASSOCIATION WITH CHRONIC ABDOMINAL PAIN
The role of H. pylori in chronic or recurrent abdominal pain without underlying ulceration is a frequent diagnostic dilemma.
- Lack of Causal Link: Meta-analyses of multiple pediatric trials show absolutely no evidence linking general recurrent abdominal pain to H. pylori infection in children.
- Specific Pain Pattern: Epigastric pain is the only pain phenotype demonstrating a significant statistical association with H. pylori infection.
- Underlying Organic Disease: Abdominal pain is definitively linked to H. pylori only when the gastritis has progressed to secondary structural damage, such as duodenal or gastric peptic ulceration (PUD).
- Diagnostic Recommendations: Routine screening for H. pylori is strictly not recommended in children fulfilling Rome IV criteria for functional abdominal pain without alarm signs.
- Justified Testing: Investigation is justified exclusively for suspected organic disease (PUD), refractory iron deficiency anemia, or chronic idiopathic thrombocytopenic purpura.
CLINICAL EVALUATION & DIAGNOSIS
Endoscopic (Invasive) Testing
- Gold Standard: Esophagogastroduodenoscopy (EGD) with mucosal biopsy.
- Visual Findings: Hallmark pediatric finding is marked antral nodularity (gooseflesh or cobblestone appearance).
- Biopsy Protocol: Minimum 6 samples (two from antrum, two from corpus for histology; remaining for culture/rapid urease).
- Histology: Giemsa or Warthin-Starry silver stain highlights organisms adhering to epithelium; accompanied by severe neutrophilic and lymphocytic infiltrate.
- Rapid Urease Test: Rapid bedside detection of ammonia production in biopsy gel medium.
Non-Invasive Testing
- Stool Antigen Test: Monoclonal ELISA highly accurate (Sensitivity 97%, Specificity 97%). Preferred for initial diagnosis and confirming post-treatment eradication.
- 13C-Urea Breath Test (UBT): Highly sensitive/specific in children >6 years. Detects expired 13CO2 generated by bacterial urease.
- Serology (IgG/IgA): Unreliable; poor specificity; cannot distinguish active from past infection. Strictly not recommended for clinical use.
MANAGEMENT PROTOCOL
First-Line Eradication Therapy
- Target: Achieve ≥90% eradication rate on initial attempt.
- Duration: 10 to 14 days.
- Standard Triple Therapy: High-dose Proton Pump Inhibitor (PPI) + Amoxicillin + Clarithromycin (or Metronidazole depending on local resistance patterns).
Rescue / Salvage Therapy
Indicated for primary treatment failure or proven antimicrobial resistance.
- Sequential Therapy: 10-day regimen; PPI + Amoxicillin for 5 days, immediately followed by PPI + Clarithromycin + Metronidazole/Tinidazole for 5 days.
- Bismuth-Based Quadruple Therapy: PPI + Bismuth salts + Amoxicillin + Metronidazole. Highly effective in dual-resistance settings.
- Eradication Confirmation: Mandatory for all treated patients. Perform non-invasive testing (Stool antigen or UBT) strictly 4-8 weeks post-treatment completion and at least 2 weeks after discontinuing PPI therapy.